GGrantIndex
← Leaderboards

Wilma J Lim

University Of North Carolina Chapel Hill

$2,704,196
Attributed
$2,704,196
Total exposure
5
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$2,704,196 · 5

By mechanism

M01$2,704,196 · 5

Top collaborators

No co-investigators on record.

Most similar at University Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectClinical ResearchAids TherapyHuman Therapy EvaluationHiv InfectionsCombination ChemotherapyDrug Screening /EvaluationPediatric AidsPharmacokineticsZidovudineHuman Pregnant SubjectInfant Human (0-1 Year)ChemopreventionVertical TransmissionAids Education /PreventionHuman Immunodeficiency VirusAntiaids AgentChild (0-11)Adolescence (12-20)Antiviral AgentsPlacental TransferAntiviral AntibodyCase HistoryCognition

Grant awards (32)

PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$190,747
M01 · FY2002 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$190,747
M01 · FY2002 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$190,747
M01 · FY2002 · RR
SAFETY/EFFICACY OF COMBINATION 1592U89/ZDV/3TC VERSUS ZDV/3TC IN HIV CHILDREN$190,747
M01 · FY2002 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$294,555
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$294,555
M01 · FY2001 · RR
SAFETY/EFFICACY OF COMBINATION 1592U89/ZDV/3TC VERSUS ZDV/3TC IN HIV CHILDREN$294,555
M01 · FY2001 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$294,555
M01 · FY2001 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$190,747
M01 · FY2001 · RR
SAFETY/EFFICACY OF COMBINATION 1592U89/ZDV/3TC VERSUS ZDV/3TC IN HIV CHILDREN$190,747
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$190,747
M01 · FY2001 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$190,747
M01 · FY2001 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$0
M01 · FY2000 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$0
M01 · FY2000 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$0
M01 · FY2000 · RR
NEVIRAPINE IN MATERNAL FETAL TRANSMISSION IN PREGNANT HIV WOMEN$0
M01 · FY2000 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$0
M01 · FY2000 · RR
ANTIRETROVIRAL MANAGEMENT FOR PEDIATRIC HIV PATIENTS$0
M01 · FY2000 · RR
ANTIRETROVIRAL MANAGEMENT FOR PEDIATRIC HIV PATIENTS$0
M01 · FY2000 · RR
ANTIRETROVIRAL MANAGEMENT FOR PEDIATRIC HIV PATIENTS$0
M01 · FY2000 · RR
ANTIRETROVIRAL MANAGEMENT FOR PEDIATRIC HIV PATIENTS$0
M01 · FY2000 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$0
M01 · FY2000 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$0
M01 · FY2000 · RR
HIVIG MATERNAL FETAL TRANSMISSION IN PREGNANT WOMEN AND NEWBORNS$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL OF HIV (ACTG 219)$0
M01 · FY2000 · RR
COMBINATION OF 1592U89/ZDV/3TC VS ZDV/3TC/1294H IN HIV CHILDREN$0
M01 · FY2000 · RR
COMBINATION OF 1592U89/ZDV/3TC VS ZDV/3TC/1294H IN HIV CHILDREN$0
M01 · FY2000 · RR
COMBINATION OF 1592U89/ZDV/3TC VS ZDV/3TC/1294H IN HIV CHILDREN$0
M01 · FY2000 · RR
COMBINATION OF 1592U89/ZDV/3TC VS ZDV/3TC/1294H IN HIV CHILDREN$0
M01 · FY2000 · RR